'Maximising Returns from Life Science Innovation'
Whether addressing global health challenges, sustainability, economics, or inclusion & equality, there has perhaps never been such collective drive and desire to ensure all stakeholders can participate in, and derive benefit from, scientific and business innovation.
The 2022 Keynote Programme at Genesis will explore how innovation in Life Sciences is leading to inclusive stakeholder rewards.
Tuesday 6 December 2022 - Genesis Eve Networking Drinks
See 'Fringe Events' for more information
Wednesday 7 December 2022 - Keynote Programme
| 08.30 | Registration |
| 09.00 | Welcome from One Nucleus |
| Jon Green, One Nucleus | |
 |
|
| 09.10 | Keynote Address: Winners & Losers 2022 |
| Mike Ward, Clarivate | |
 |
|
| 09.30 | Panel: Innovative Dealmaking for Innovative Solutions |
| A discussion to review the latest trends in life science investment and partnering deals, what have previous financing cycles taught us? | |
|
Moderator: Amy Brown, Evaluate Vantage Panelists: Julie Simmonds, Panmure Gordon, James Fry, Mills & Reeve, Will Walker-Arnott, Charles Stanley Wealth Management, Kate Rowley, Global Bio Fund, Jérôme Van Biervliet, VIB |
|
| 10.30 | Coffee Break |
| 11.00 | www.LifeSciences.2023 |
| Who will be the stakeholders shaping and disrupting the sector in 2023 and beyond? What – technologies, in R&D, drug delivery or related field will provide the best solutions for patients? When will we see the impacts of the above take effect? |
|
|
Moderator: Paul Branthwaite, tranScrip
Panelists: Laura Lane, Eli Lilly, David Roblin, Relation Therapeutics, Miguel Forte, Bone Therapeutics, Cristina Oliva, BerGenBio |
|
| 11.50 | Pre-Lunch Debate: This House Believes: |
|
“The Golden Triangle is a Better Ecosystem to Grow a Life Science Company Than Greater Boston” Following the One Nucleus trade visit to Boston in September 2022, the delegation will feedback their views on what they discovered when comparing these two key life science clusters. The debate will close with an audience vote in favour or in opposition to the title statement |
|
|
Presiding: Mike Ward, Clarivate
Debaters: Catherine Stace, Domainex, Max Bryan, Bidwells, John McCafferty, Maxion Therapeutics, Nick Foster, Metrion Biosciences, Jiahao Huang, Nuclera |
|
| 12.30 | Lunch |
| 13.30 | Panel: Is Technology Diversifying Biomedical R&D Outputs? |
|
The ability to generate, collect and analyse data from diverse sources has never advanced more rapidly. The panel will discuss whether this is leading to greater diversity in areas such as, target selection & drug design, patient stratification in clinical trials, scale of collaboration and skills |
|
|
Moderator: Lisa Melton, Nature Biotechnology
Panelists: Rowan Gardner, PrecisionLife, Andy Richards, Ieso Digital Health, Victor Neduva, MSD |
|
| 14.20 | Panel: Value Creation and Sharing in a Converging World |
| As R&D evolves to include ever-increasing reliance on Big Data/AI, external partnerships and global markets, how do we collaborate to protect, capture and share the created value equitably? | |
|
Moderator: Victoria English, MedNous
Panelists: Hannah Sore, PharmEnable, Chris Wayman, EY, Claire Smith, Bristows, Nuno Alves, Astellas Pharma, Peter Peumans, imec |
|
| 15.00 | Coffee Break |
| 15.30 | So, what do you think? |
|
A chance to listen in to a conversation you wish you had heard as two leading lights share their thoughts on a key question facing the life science sector right now |
|
| 15.50 | Panel: The Anatomy of a Life Science Leader |
|
The panel will discuss what successful traits of leadership are required to build an innovation-led life science company |
|
|
Moderator: Mike Ward, Clarivate
|
|
| 16.50 | Closing Remarks |
|
Tony Jones, One Nucleus
|
|
| 17.00 | Drinks Reception |
| 18.00 | Close |
